Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Ignore at your own risk

Information threats need to be addressed calmly and strategically

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

- PMLiVE

FDA approval for Nova’s leukaemia drug

Purixan expected to provide more accurate dosing for children

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

- PMLiVE

Bayer outlines some of its digital health needs

Wants to work with startups in areas such as oncology and men's health

- PMLiVE

Chiesi launches Flogoprofen website

Targets consumers and health professionals in Spain

- PMLiVE

Interview: Bruno Strigini, MSD

MSD’s president, Europe and Canada, on how pharma is adapting to the market’s new reality

- PMLiVE

Icon appoints Hugh Brady to board

He is former president of University College Dublin

- PMLiVE

Otsuka wins approval for TB drug Deltyba

Second drug approved by EC in 2014 for multidrug resistant tuberculosis

- PMLiVE

Breo off to slow start in US as Advair slips, says GSK

And China issues continue to affect sales performance

- PMLiVE

Reckitt Benckiser backtracks on Merck OTC unit

Ends negotiations to add to consumer health division

Michael Fleming joins biosimilars firm Coherus

He has experience at Elan, Genentech and GSK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links